Recently, Hengsai Bio completed a billion-level A round of financing, which was led by Fuhui Venture Capital, with Qinzhi Capital and Kaiqi Kangying following up.
Hengsai Biotech is a dendritic cell tumor therapeutic vaccine developer, mainly engaged in the research and industrialization of a new generation of personalized dendritic cell tumor therapeutic vaccines (DC vaccines). The company has successfully built the Eco-DCVax platform, aiming to break through industrialization technological barriers and develop high-quality DC vaccine products with independent intellectual property rights that are global First-in-Class, safe, efficient, and convenient for administration. The developed product — a therapeutic dendritic cell vaccine — provides new approaches and strategies for treating diseases in urgent clinical need of effective therapies, such as recurrent and refractory tumors, chronic viral infections, and autoimmune diseases.
Dr. Hui Ning Liu, founder and CEO of Hengsai Bio, stated: Hengsai Bio possesses a relatively mature DC vaccine preparation process and a scientifically compliant quality control system. We are very grateful for the recognition and trust from our investors in this round—Fuhui Venture Capital, Qinzhi Capital, and Kaiqi Kangying—and also for the support from Maibai Capital. This round of financing will help us advance the expansion of our product pipeline and clinical applications. The Hengsai team will continue to be guided by clinical needs and driven by technological innovation to develop safer, more effective, and accessible DC vaccines.
The investment team of Fuhui Venture Capital stated: "Fuhui Venture Capital has a deep strategic cooperation with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Zhongshan Municipal Government, and is committed to promoting the establishment and development of more high-quality innovative pharmaceutical companies in Cuiheng New District, Zhongshan City. Hengsai Biotech, as a leading company in DC cell therapy in China, is a representative of the high-quality enterprises we have long-term cooperated with and served. We will continue to support the rapid development of Hengsai Biotech and help it grow into a global leader in DC cell therapy."